In-Silico and In-Vitro Analysis of the Novel Hybrid Comprehensive Stage II Operation for Single Ventricle Circulation.
Arka DasMarwan HameedRay PratherMichael FariasEduardo DivoAlain KassabDavid NykanenWilliam M DeCampliPublished in: Bioengineering (Basel, Switzerland) (2023)
Single ventricle (SV) anomalies account for one-fourth of all congenital heart disease cases. The existing palliative treatment for this anomaly achieves a survival rate of only 50%. To reduce the trauma associated with surgical management, the hybrid comprehensive stage II (HCSII) operation was designed as an alternative for a select subset of SV patients with the adequate antegrade aortic flow. This study aims to provide better insight into the hemodynamics of HCSII patients utilizing a multiscale Computational Fluid Dynamics (CFD) model and a mock flow loop (MFL). Both 3D-0D loosely coupled CFD and MFL models have been tuned to match baseline hemodynamic parameters obtained from patient-specific catheterization data. The hemodynamic findings from clinical data closely match the in-vitro and in-silico measurements and show a strong correlation (r = 0.9). The geometrical modification applied to the models had little effect on the oxygen delivery. Similarly, the particle residence time study reveals that particles injected in the main pulmonary artery (MPA) have successfully ejected within one cardiac cycle, and no pathological flows were observed.
Keyphrases
- pulmonary artery
- congenital heart disease
- pulmonary hypertension
- coronary artery
- pulmonary arterial hypertension
- end stage renal disease
- electronic health record
- chronic kidney disease
- ejection fraction
- molecular docking
- mitral valve
- left ventricular
- palliative care
- newly diagnosed
- heart failure
- aortic valve
- patient reported outcomes
- replacement therapy
- molecular dynamics simulations
- ultrasound guided
- atrial fibrillation